Neurophet develops AI-driven medical software for neurology, including brain MRI and PET analysis, stimulation simulation, and region-of-interest research tools. Its product suite includes Neurophet AQUA (brain MRI imaging analysis), Neurophet SCALE PET (brain PET scan analysis), Neurophet tES/TMS Lab (stimulation simulation), and Neurophet SegPlus (ROI research tool). The company focuses on diagnosis support, treatment guides, and treatment-device software for brain diseases using advanced AI. In November 2023 Neurophet secured KRW 20.0 billion in a Series C financing. The firm plans to use the funds to release a comprehensive Alzheimer’s dementia solution next year. The funding is intended to support continued product development and commercial rollout of its AI-driven brain imaging offerings.

Total raised

$15M

Funding rounds

1

Latest round

Series C

Latest activity

Nov 2023